Haploidentical CD7 CAR T-cells induced remission in a patient with TP53 mutated relapsed and refractory early T-cell precursor lymphoblastic leukemia/lymphoma

Patients with relapsed/refractory early T-cell precursor lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) respond poorly to traditional therapy and have dismal prognosis. CD7 is a promising therapeutic targets for chimeric antigen receptor modified T cell therapy (CART) due to its widely expression in...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Hai-ping, Cui, Wei, Cui, Qing-ya, Zhu, Wen-juan, Meng, Hui-min, Zhu, Min-qing, Zhu, Xia-ming, Yang, Lin, Wu, De-pei, Tang, Xiao-wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8822664/
https://www.ncbi.nlm.nih.gov/pubmed/35130959
http://dx.doi.org/10.1186/s40364-022-00352-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8822664/
https://www.ncbi.nlm.nih.gov/pubmed/35130959
http://dx.doi.org/10.1186/s40364-022-00352-w

Ejemplares similares